Crohn's Disease and Colitis Trial, Recruiting NCT07487480 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT07487480
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 75 years of age
  • People who have been diagnosed with Crohn's disease for at least 3 months
  • People whose Crohn's disease is considered moderate to severe, based on a standard scoring system called the CDAI (confirm with trial site)
  • People who have previously been treated with a standard dose of ustekinumab and either did not respond to it from the start, responded at first but then stopped responding over time, or had to stop taking it due to side effects

Who may not be able to join:

  • People who have previously been treated with a type of medication called an anti-IL-23p19 therapy, which includes a drug called guselkumab
  • People who currently have an active gut infection, a bowel blockage, short bowel syndrome, a stoma, or who had an abscess in the abdomen within the past 8 weeks
  • People with a history of cancer (with some exceptions for certain skin cancers), active tuberculosis, or a serious opportunistic infection
  • People who are pregnant, breastfeeding, or planning to become pregnant during the time the study would be running

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 008619857407061

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 February 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of patients achieving clinical remission (CDAI <150 or HBI <4) at Week 52.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov